A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III TrialGian Maria Zaccaria, Marco Ladetto, Simone Ferrero et al.|Cancers|2021Cited by 13
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real‐world setting: Interim results of the Italian observational study (ROMEI)Massimo Breccia, Filíppo Gherlinzoni, Alessandra Malato et al.|Cancer|2025Cited by 10